Unknown statusInterventionalPhase 1Last updated Mar 24, 2025

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

A Phase 1, Multicenter, Open-Label Study of CB-010, a CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy in Patients With Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)

Overview

ClinicalTrials.gov ID: NCT04637763
Lead Sponsor: Caribou Biosciences, Inc.INDUSTRY
Brief Summary: CB010A is a study evaluating safety, emerging efficacy, pharmacokinetics and immunogenicity of CB-010 in adults with relapsed/refractory B cell non-Hodgkin lymphoma after lymphodepletion consisting of cyclophosphamide and fludarabine.
Study Type: Interventional

Status

Overall Status: Unknown status
Start Date: May 26, 2021Actual
Primary Completion Date: Aug 2025Estimated
Completion Date: Sep 2025Estimated

Study Record Dates

First Submitted: Nov 16, 2020
First Submitted that Met QC Criteria: Nov 16, 2020
First Posted: Nov 20, 2020Actual
Last Update Submitted that Met QC Criteria: Mar 21, 2025
Last Update Posted: Mar 24, 2025Actual
Last Verified: May 2024

NCT06128044Terminated

CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

NCT06752876Withdrawn

CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy, in Patients With Refractory Systemic Lupus Erythematosus (GALLOP)

NCT05722418Recruiting

CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

NCT03154775Unknown status

Study of Safety and Efficacy of C-CAR011 in B-NHL Patients

NCT05094206Terminated

CAR20.19.22 T-cells in Relapsed, Refractory B-cell Malignancies

NCT04712864Unknown status

Study of CD4-Targeted Chimeric Antigen Receptor T-Cells (CD4- CAR-T) in Subjects With Relapsed or Refractory T-Cell Lymphoma